Anti-BG8 (Lewisᵞ / Lewis Y blood group antigen) CE/IVD antibodies are immunohistochemical reagents used for the detection of the tumor-associated carbohydrate antigen Lewis Y, which is expressed in a range of epithelial malignancies, including lung carcinomas.

Biological Significance of Lewisᵞ (BG8) in Pulmonary Pathology

• Lewisᵞ (BG8) is a fucosylated carbohydrate antigen expressed on glycoproteins and glycolipids of epithelial cell surfaces and is involved in normal glycosylation processes.
• In malignant transformation, Lewisᵞ expression may become upregulated or aberrantly expressed, reflecting tumor-associated alterations in cell surface glycosylation.
• Peer-reviewed studies in cancer glycobiology and lung tumor immunophenotyping have reported Lewisᵞ expression in multiple epithelial malignancies, including subsets of non-small cell lung carcinoma (NSCLC), supporting its characterization as a tumor-associated carbohydrate antigen.
• In pulmonary pathology, Lewisᵞ expression has been investigated as part of broader research into tumor glycosylation patterns and epithelial differentiation markers, rather than as a lineage-defining biomarker.

Diagnostic Utility of BG8 (Lewisᵞ) in Pulmonary Pathology

• Immunohistochemical detection of Lewisᵞ has been reported in the literature as an adjunctive marker in studies evaluating differential immunoprofiles of pulmonary epithelial tumors, including adenocarcinoma and other NSCLC subtypes.
• Published research has explored BG8 expression patterns in lung carcinomas to better characterize tumor-associated glycoepitope expression, contributing to morphological and molecular correlation studies in surgical pathology.
• Its expression has also been investigated in comparative tumor studies involving epithelial neoplasms, including work examining differential glycosylation between carcinoma subtypes and mesothelial lesions, although it is not a primary diagnostic marker in standard routine panels.
• Overall, BG8 (Lewisᵞ) is best regarded as a research-supported ancillary marker that may contribute supportive information within broader immunohistochemical panels in pulmonary tumor characterization.

Key Features of CE/IVD Anti-BG8 (Lewisᵞ) Antibodies for IHC

• Validated for immunohistochemistry on formalin-fixed, paraffin-embedded (FFPE) tissue sections, supporting standardized use in histopathology workflows.
• Monoclonal anti-Lewisᵞ antibodies provide specific recognition of tumor-associated Lewis Y glycoepitopes, as demonstrated in experimental and diagnostic immunohistochemistry applications.
• Designed for use in in vitro diagnostic (CE/IVD) settings, enabling controlled and reproducible detection of Lewisᵞ antigen expression in tissue specimens.
• Suitable for incorporation into multi-marker immunohistochemical panels used in pulmonary tumor characterization and research-oriented studies of epithelial differentiation and tumor glycosylation.